Opendata, web and dolomites

ADVANTAGE SIGNED

ADvanced Validation of A Novel TB Active disease diagnostic to address Global unmet needs: a European consortium approach

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ADVANTAGE project word cloud

Explore the words cloud of the ADVANTAGE project. It provides you a very rough idea of what is the project "ADVANTAGE" about.

regulatory    reduce    packages    microfluidic    transitioning    hold    platform    biosensia    proteinlogic    meet    cell    mediated    validation    eradicate    commercialisation    advantage    slow    yield    global    company    diagnostic    analytes    practises    healthcare       bn    security    demonstrated    serum    clinical    despite    commercial    care    uk    successful    structured    poc    supply    tuberculosis    improvements    biomarkers    proof    unmet    samples    reader    million    tb    biomarker    clear    massive    variety    successfully    burden    proven    breaking    ground    profile    disruptive    creation    private    analytical    investment    companies    costly    human    time    400    patient    panel    jobs    globally    laboratory    diagnostics    summary    active    point    instrument    ing    deaths    reagents    standards    elusive    rapid    assay    eight    stimulate    plus    accounting    protein    cartridge    performance    risks    poorly    validated    selective    efforts    confirm   

Project "ADVANTAGE" data sheet

The following table provides information about the project.

Coordinator
PROTEINLOGIC LIMITED 

Organization address
address: SHAKESPEARE HOUSE 42 NEWMARKET ROAD
city: CAMBRIDGE CAMBRIDGESHIRE
postcode: CB5 8EP
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://www.proteinlogic.com
 Total cost 3˙893˙307 €
 EC max contribution 3˙583˙396 € (92%)
 Programme 1. H2020-EU.3.1. (SOCIETAL CHALLENGES - Health, demographic change and well-being)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-2-2014
 Funding Scheme SME-2
 Starting year 2015
 Duration (year-month-day) from 2015-07-01   to  2018-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PROTEINLOGIC LIMITED UK (CAMBRIDGE CAMBRIDGESHIRE) coordinator 2˙921˙750.00
2    BIOSENSIA LIMITED IE (DUBLIN) participant 661˙646.00

Map

 Project objective

Tuberculosis (TB) remains an EU and global healthcare priority resulting in over 1.4 million deaths each year. Despite this and efforts to reduce TB by the EU commission, the WHO and others, a simple, rapid, diagnostic test for active tuberculosis (TB) remains elusive. Current diagnostic procedures, while accounting for over $1 bn globally, are poorly selective for active TB, hold risks for healthcare personnel, are slow to yield results and costly.

The large potential and high unmet need provide a clear target for commercialisation of a point-of-care (POC) test. Using over 400 clinical samples, ProteinLogic (a UK based diagnostics company) have demonstrated proof of concept for a ground-breaking approach using a panel of protein biomarkers on human serum samples that profile the cell mediated patient response to TB.

The objectives of the eight structured work packages within this three year project are to build on the validation of the biomarker TB panel transitioning from a laboratory assay to Biosensia’s novel microfluidic POC platform that has already been successfully proven with a variety of human analytes. Reagents will be developed as part of this project to ensure reduced costs and security of commercial supply. A unique instrument reader plus TB cartridge-based product will be developed to meet EU regulatory standards. The products will be validated in order to confirm analytical and clinical performance, and to provide evidence of major time, cost & performance improvements compared to current TB testing practises. Successful commercialisation will lead to the creation of over 30 new jobs and will stimulate further private investment in each of the companies.

In summary, ADVANTAGE has the potential to deliver a disruptive POC TB diagnostic test that can help eradicate the massive TB burden not only in EU but also globally.

 Deliverables

List of deliverables.
Clone scale Websites, patent fillings, videos etc. 2019-05-30 13:18:55

Take a look to the deliverables list in detail:  detailed list of ADVANTAGE deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ADVANTAGE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ADVANTAGE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.;H2020-EU.2.3.1.)

PREPARE (2016)

Preventing Respiratory Events through Proactive Assessment of Respiratory Effort

Read More  

SIME-LMT (2015)

Development of a digital diagnostics rapid Lung Maturity Test (LMT) for premature infants, to assist neonatologists in the diagnosis of Respiratory Distress Syndrome at birth

Read More  

ADVANTAGE (2015)

ADvanced Validation of A Novel TB Active disease diagnostic to address Global unmet needs: a European consortium approach

Read More